Title |
nab-Paclitaxel–Based Therapy in Underserved Patient Populations: The ABOUND.PS2 Study in Patients With NSCLC and a Performance Status of 2
|
---|---|
Published in |
Frontiers in oncology, July 2018
|
DOI | 10.3389/fonc.2018.00253 |
Pubmed ID | |
Authors |
Ajeet Gajra, Nagla Abdel Karim, Deborah A. Mulford, Liza Cosca Villaruz, Marc Ryan Matrana, Haythem Y. Ali, Edgardo S. Santos, Tymara Berry, Teng Jin Ong, Alexandra Sanford, Katayoun Amiri, David R. Spigel |
Abstract |
The phase II ABOUND.PS2 study (NCT02289456) assessed safety/tolerability of a first-line modified nab-paclitaxel/carboplatin regimen for patients with advanced non-small cell lung cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2. Chemotherapy-naive patients with stage IIIB/IV NSCLC and ECOG PS 2 received four cycles of nab-paclitaxel 100 mg/m2 days 1 and 8 plus carboplatin area under the curve 5 day 1 q3w (induction). Patients without progression received nab-paclitaxel monotherapy (100 mg/m2 days 1 and 8 q3w) until progression/unacceptable toxicity. Primary endpoint: percentage of patients discontinuing induction due to treatment-emergent adverse events (TEAEs). 11/40 treated patients (27.5%; 95% CI, 14.60-43.89) discontinued chemotherapy induction due to TEAEs; 16/40 (40.0%) continued nab-paclitaxel monotherapy. Median progression-free and overall survival were 4.4 (95% CI, 2.99-7.00) and 7.7 (95% CI, 4.93-13.17) months. Grade 3/4 TEAEs during induction included neutropenia (22.5%), anemia (17.5%), thrombocytopenia (5.0%), and peripheral neuropathy (2.5%). This nab-paclitaxel-based regimen was tolerable in patients with advanced NSCLC and ECOG PS 2, with efficacy comparable to historical chemotherapy data. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 2 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 2 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 13 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Lecturer | 2 | 15% |
Student > Ph. D. Student | 2 | 15% |
Researcher | 2 | 15% |
Student > Bachelor | 1 | 8% |
Other | 1 | 8% |
Other | 1 | 8% |
Unknown | 4 | 31% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 5 | 38% |
Pharmacology, Toxicology and Pharmaceutical Science | 1 | 8% |
Psychology | 1 | 8% |
Nursing and Health Professions | 1 | 8% |
Unknown | 5 | 38% |